Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

BACKGROUND: The optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST) in a large retrospective cohort of GBM patients treated with BV at different recurrence...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Piccioni, David E., Selfridge, Julia, Mody, Reema R., Chowdhury, Reshmi, Li, Sichen, Lalezari, Shadi, Wawrzynski, James, Quan, Jennifer, Zurayk, Mira, Chou, Arthur P., Sanchez, Desiree E., Liau, Linda M., Ellingson, Benjamin M., Pope, Whitney B., Nghiemphu, Phioanh L., Green, Richard M., Wang, He-jing, Yong, William H., Elashoff, Robert, Cloughesy, Timothy F., Lai, Albert
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4022228/
https://ncbi.nlm.nih.gov/pubmed/24627236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados